MSH6 and gastric cancer: This summary demonstrated lifetime risk was 5–7% for MLH1 carriers, 0.2–9% for MSH2 and EPCAM carriers, and <1–7.9% in MSH6 carriers, and importantly notes that the risk for PMS2 carriers is unknown, illustrating the uncertainty of whether gastric cancer risk is increased for PMS2 carriers.